<DOC>
	<DOCNO>NCT01822418</DOCNO>
	<brief_summary>Major depressive episode ( MDEs ) occur frequently course psychotic disorder , several antidepressive agent successfully apply . The new melatonergic antidepressant agomelatine ( AGO ) appear promising treatment MDEs schizophrenia several reason . The investigator plan test efficacy tolerability AGO antidepressive treatment schizophrenia . For task , investigator plan enrol 27 schizophrenic patient open , single-armed , prospective clinical trial agomelatine .</brief_summary>
	<brief_title>Agomelatine Treatment Depression Schizophrenia ( AGOPSYCH )</brief_title>
	<detailed_description>Major depressive episode ( MDEs ) occur frequently course psychotic disorder , several antidepressive agent successfully apply . The new melatonergic antidepressant agomelatine ( AGO ) appear promising treatment MDEs schizophrenia several reason : 1 . AGO provide unique pharmacological profile combine antidepressive potency , sleep regulation enhancement frontocortical dopaminergic activity 5-HT-2C-blockade . 2 . AGO might exert favourable effect cognition . 3 . While pharmacokinetic interaction generally possible , major influence antipsychotic substance unlikely due metabolism cytochrome isoenzymes CYP1A2 CYP2C9/19 . 4 . AGO characterize favourable range adverse event ( AE ) overlap typical antipsychotic AEs weight gain sexual dysfunction . Thus , risk additive effect seem small . The investigator plan enroll 27 schizophrenic patient open , single-armed , prospective clinical trial agomelatine . As predefined primary secondary endpoint , go investigate whether AGO able improve MDE severity , sleep quality , general psychosocial function well cognitive function schizophrenia without detrimental effect psychotic syndrome . Moreover , intend monitor pharmacokinetic interaction . The result obtain allow designing future randomize controlled clinical trial order improve range therapeutic option affective cognitive deficit schizophrenia .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>S 20098</mesh_term>
	<criteria>1 . Age 18 60 year . 2 . Presence MDE accord ICD10 criterion ( HAMD17 ≥ 18 CDSSScore ≥ 8 point ) . 3 . Lifetime diagnosis schizophreniaspectrum disorder accord ICD10 ( F 20 , F22 , F23 , F25 ) . 4 . Partial remission psychotic positive symptom ( PANSS positive subscore ≤ 15 point ) . 5 . Stable antipsychotic medication least 2 week ( tolerable quantitative change daily dosage ≤ 25 % ) . 6 . The patient able give inform consent . In case legal guardianship , custodian agree patient 's participation . 1 . Contraindications AGO treatment 2 . Insufficient contraception woman childbearing potential sexually active . 3 . Gravidity breastfeeding . 4 . Addiction alcohol 5 . Current abuse THC illegal substance accord ICD10 6 . Dementia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Depression</keyword>
	<keyword>Cognition</keyword>
	<keyword>Agomelatine</keyword>
	<keyword>Antidepressant</keyword>
</DOC>